Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Impact of a probiotic product on bowel habits and microbial profile in participants with functional constipation: A randomized controlled trial.

Martoni CJ, Evans M, Chow CT, Chan LS, Leyer G.

J Dig Dis. 2019 Sep;20(9):435-446. doi: 10.1111/1751-2980.12797. Epub 2019 Aug 1.

2.

Lactobacillus acidophilus DDS-1 Modulates Intestinal-Specific Microbiota, Short-Chain Fatty Acid and Immunological Profiles in Aging Mice.

Vemuri R, Gundamaraju R, Shinde T, Perera AP, Basheer W, Southam B, Gondalia SV, Karpe AV, Beale DJ, Tristram S, Ahuja KDK, Ball M, Martoni CJ, Eri R.

Nutrients. 2019 Jun 7;11(6). pii: E1297. doi: 10.3390/nu11061297.

3.

Lactobacillus acidophilus DDS-1 Modulates the Gut Microbiota and Improves Metabolic Profiles in Aging Mice.

Vemuri R, Shinde T, Gundamaraju R, Gondalia SV, Karpe AV, Beale DJ, Martoni CJ, Eri R.

Nutrients. 2018 Sep 6;10(9). pii: E1255. doi: 10.3390/nu10091255.

4.

A human origin strain Lactobacillus acidophilus DDS-1 exhibits superior in vitro probiotic efficacy in comparison to plant or dairy origin probiotics.

Vemuri R, Shinde T, Shastri MD, Perera AP, Tristram S, Martoni CJ, Gundamaraju R, Ahuja KDK, Ball M, Eri R.

Int J Med Sci. 2018 May 26;15(9):840-848. doi: 10.7150/ijms.25004. eCollection 2018.

5.

Changes in bile acids, FGF-19 and sterol absorption in response to bile salt hydrolase active L. reuteri NCIMB 30242.

Martoni CJ, Labbé A, Ganopolsky JG, Prakash S, Jones ML.

Gut Microbes. 2015;6(1):57-65. doi: 10.1080/19490976.2015.1005474.

6.

Bacterial bile metabolising gene abundance in Crohn's, ulcerative colitis and type 2 diabetes metagenomes.

Labbé A, Ganopolsky JG, Martoni CJ, Prakash S, Jones ML.

PLoS One. 2014 Dec 17;9(12):e115175. doi: 10.1371/journal.pone.0115175. eCollection 2014.

7.

Emerging science of the human microbiome.

Jones ML, Ganopolsky JG, Martoni CJ, Labbé A, Prakash S.

Gut Microbes. 2014 Jul 1;5(4):446-57. doi: 10.4161/gmic.29810. Epub 2014 Jul 11. Review.

PMID:
25013912
8.

The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention.

Jones ML, Martoni CJ, Ganopolsky JG, Labbé A, Prakash S.

Expert Opin Biol Ther. 2014 Apr;14(4):467-82. doi: 10.1517/14712598.2014.880420. Epub 2014 Jan 30. Review.

PMID:
24479734
9.

Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial.

Jones ML, Martoni CJ, Ganopolsky JG, Sulemankhil I, Ghali P, Prakash S.

Expert Opin Biol Ther. 2013 Dec;13(12):1643-51. doi: 10.1517/14712598.2013.833601. Epub 2013 Sep 28.

PMID:
24074303
10.

Oral supplementation with probiotic L. reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial.

Jones ML, Martoni CJ, Prakash S.

J Clin Endocrinol Metab. 2013 Jul;98(7):2944-51. doi: 10.1210/jc.2012-4262. Epub 2013 Apr 22.

PMID:
23609838
11.

Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications.

Jones ML, Tomaro-Duchesneau C, Martoni CJ, Prakash S.

Expert Opin Biol Ther. 2013 May;13(5):631-42. doi: 10.1517/14712598.2013.758706. Epub 2013 Jan 28. Review.

PMID:
23350815
12.

Letter to the editor regarding the report of Duboc et al: Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel disease.

Jones ML, Martoni CJ, Prakash S.

Gut. 2013 Apr;62(4):654-5. doi: 10.1136/gutjnl-2012-303867. Epub 2012 Nov 12. No abstract available.

PMID:
23148122
13.

Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.

Jones ML, Martoni CJ, Di Pietro E, Simon RR, Prakash S.

Regul Toxicol Pharmacol. 2012 Jul;63(2):313-20. doi: 10.1016/j.yrtph.2012.04.003. Epub 2012 Apr 25.

PMID:
22561556
14.

Evaluation of safety and tolerance of microencapsulated Lactobacillus reuteri NCIMB 30242 in a yogurt formulation: a randomized, placebo-controlled, double-blind study.

Jones ML, Martoni CJ, Tamber S, Parent M, Prakash S.

Food Chem Toxicol. 2012 Jun;50(6):2216-23. doi: 10.1016/j.fct.2012.03.010. Epub 2012 Mar 15.

PMID:
22425689
15.

Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults.

Jones ML, Martoni CJ, Parent M, Prakash S.

Br J Nutr. 2012 May;107(10):1505-13. doi: 10.1017/S0007114511004703. Epub 2011 Nov 9.

PMID:
22067612

Supplemental Content

Loading ...
Support Center